{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:39:00Z","timestamp":1779367140211,"version":"3.53.0"},"reference-count":23,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T00:00:00Z","timestamp":1585872000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPD"],"published-print":{"date-parts":[[2020,4,3]]},"DOI":"10.3233\/jpd-191841","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T09:31:30Z","timestamp":1579253490000},"page":"543-558","source":"Crossref","is-referenced-by-count":32,"title":["EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson\u2019s Disease"],"prefix":"10.1177","volume":"10","author":[{"given":"Caroline M.","family":"Tanner","sequence":"first","affiliation":[{"name":"University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[{"name":"University of Kansas Medical Center, Kansas City, KS, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Oertel","sequence":"additional","affiliation":[{"name":"Philipps University, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H.","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Parkinson\u2019s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reed","family":"Johnson","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Chernick","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Hubble","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc., Emeryville, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JPD-191841_ref1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3233\/JPD-181565","article-title":"Prevalence of dyskinesia and OFF by 30-minute intervals through the day and assessment of daily episodes of dyskinesia and OFF: Novel analyses of diary data from Gocovri pivotal trials","volume":"9","author":"Hauser","year":"2019","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-191841_ref3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s40262-018-0663-4","article-title":"Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia","volume":"58","author":"Hauser","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.3233\/JPD-191841_ref4","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1002\/mds.27131","article-title":"Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 3)","volume":"32","author":"Oertel","year":"2017","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191841_ref5","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1001\/jamaneurol.2017.0943","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID study): A randomized clinical trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.3233\/JPD-191841_ref6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40263-018-0498-4","article-title":"Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease","volume":"32","author":"Elmer","year":"2018","journal-title":"CNS Drugs"},{"key":"10.3233\/JPD-191841_ref7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s40263-018-0510-z","article-title":"Author correction to: Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson\u2019s disease","volume":"32","author":"Elmer","year":"2018","journal-title":"CNS Drugs"},{"key":"10.3233\/JPD-191841_ref8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3233\/JPD-171134","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASE LID 2 Study): Interim results of an open-label safety study","volume":"7","author":"Hauser","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"10.3233\/JPD-191841_ref9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/mdc3.12595","article-title":"Parkinson\u2019s patients with dyskinesia switched from immediate release amantadine to open-label ADS-5102","volume":"5","author":"Isaacson","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.3233\/JPD-191841_ref10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: A clinico-pathological study of 100 cases","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JPD-191841_ref11","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191841_ref12","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/mds.26159","article-title":"Amantadine extended release for levodopa-induced dyskinesia in Parkinson\u2019s disease (EASED Study)","volume":"30","author":"Pahwa","year":"2015","journal-title":"Mov Disord"},{"key":"10.3233\/JPD-191841_ref13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2018.08.018","article-title":"Minimal clinically important difference for the historic parts of the Unified Dyskinesia Rating Scale","volume":"58","author":"Makkos","year":"2019","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-191841_ref14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002826-198904000-00003","article-title":"Falls and Parkinson\u2019s disease","volume":"12","author":"Koller","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.3233\/JPD-191841_ref15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01376517-200008000-00006","article-title":"Fall risk factors in Parkinson\u2019s disease","volume":"32","author":"Gray","year":"2000","journal-title":"J Neurosci Nurs"},{"key":"10.3233\/JPD-191841_ref16","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.parkreldis.2014.06.023","article-title":"Natural history of falls in a population-based cohort of patients with Parkinson\u2019s disease: An 8-year prospective study","volume":"20","author":"Hiorth","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JPD-191841_ref17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00702-015-1396-2","article-title":"Falls in ambulatory non-demented patients with Parkinson\u2019s disease","volume":"122","author":"Rascol","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"10.3233\/JPD-191841_ref18","first-page":"362572","article-title":"Risk of falls in Parkinson\u2019s disease: A cross-sectional study of 160 patients","volume":"2012","author":"Contreras","year":"2012","journal-title":"Parkinsons Dis"},{"key":"10.3233\/JPD-191841_ref19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","article-title":"Psychosis in Parkinson\u2019s disease: Epidemiology, pathophysiology, and management","volume":"76","author":"Chang","year":"2016","journal-title":"Drugs"},{"key":"10.3233\/JPD-191841_ref20","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch Neurol"},{"key":"10.3233\/JPD-191841_ref21","doi-asserted-by":"crossref","first-page":"307106","DOI":"10.1155\/2014\/307106","article-title":"Pharmacology of hallucinations: Several mechanisms for one single symptom?","volume":"2014","author":"Rolland","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.3233\/JPD-191841_ref22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s007260070042","article-title":"Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents\u2013toward an understanding of their favorable tolerability","volume":"19","author":"Rogawski","year":"2000","journal-title":"Amino Acids"},{"key":"10.3233\/JPD-191841_ref23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpsyt.2013.00151","article-title":"Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis","volume":"4","author":"Merritt","year":"2013","journal-title":"Front Psychiatry"},{"key":"10.3233\/JPD-191841_ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"}],"container-title":["Journal of Parkinson's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JPD-191841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:47:25Z","timestamp":1777610845000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JPD-191841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,3]]},"references-count":23,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.3233\/jpd-191841","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,3]]}}}